Tummatorn, J.; Punjajom, K.; Rodphon, W.; Ruengsangtongkul, S.; Chaisan, N.; Lumyong, K.; Thongsornkleeb, C.; Nimnual, P.; Ruchirawat, S. Chemoselective Synthesis of 1,1-Disubstituted Vinyl Triflates from Terminal Alkynes Using TfOH in the Presence of TMSN3. Org. Lett. 2019, 21, 4694–4697.

28 Dec 2019
0
0

Tummatorn, J.; Punjajom, K.; Rodphon, W.; Ruengsangtongkul, S.; Chaisan, N.; Lumyong, K.; Thongsornkleeb, C.; Nimnual, P.; Ruchirawat, S. Chemoselective Synthesis of 1,1-Disubstituted Vinyl Triflates from Terminal Alkynes Using TfOH in the Presence of TMSN3. Org. Lett. 2019, 21, 4694–4697.

Tags

Share this

Related Posts

Lertsuwan, K., Nammultriputtar, K., Nanthawuttiphan, S., Phoaubon, S., Lertsuwan, J., Thongbunchoo, J., . . . Charoenphandhu, N. (2018). Ferrous and ferric differentially deteriorate proliferation and differentiation of osteoblast-like UMR-106 cells. Biometals, 31(5), 873-889. doi:10.1007/s10534-018-0130-6
16 Jul 2018
0

Lertsuwan, K., Nammultriputtar, K., Nanthawuttiphan, S., Phoaubon, S., Lertsuwan, J., Thongbunchoo, J., . . . Charoenphandhu, N. (2018). Ferrous and ferric differentially deteriorate proliferation and differentiation of osteoblast-like UMR-106 cells. Biometals, 31(5), 873-889. doi:10.1007/s10534-018-0130-6

Lertsuwan, K., Nammultriputtar, K., Nanthawuttiphan, S., Phoaubon, S., Lertsuwan, J., Thongbunchoo, J., . . . Charoenphandhu, N. (2018). Ferrous and ferric differentially deteriorate proliferation and differentiation of osteoblast-like UMR-106 cells. Biometals, 31(5), 873-889. doi:10.1007/s10534-018-0130-6
View More

Recent Posts

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)
20 Sep 2023
0

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial)

Efficacy of Andrographis paniculata extract treatment in mild to moderate COVID-19 patients being treated with favipiravir: A double-blind, randomized, placebo-controlled study (APFaVi trial) Siripongboonsitti T, Ungtrakul T, Tawinprai K, Auewarakul C, Chartisathian W, Jansala T, Julsawad R, Soonklang K, Mahanonda N, Mahidol C Phytomedicine. 2023;119:155018.
View More